The tender offer is procedure. The deck filed alongside it is not, because it is the first time anyone can see what $2.2 billion actually bought. FB102’s entire human efficacy dataset in vitiligo is 42 patients, thirty-two on drug and ten on placebo, and the earliest comparison missed at p=0.059 before separating from Day 64 onward. argenx committed the full price on signing, in cash, with no milestones and no contingent value rights, against that. Whatever else this is, it is not a company hedging.

• The price-to-evidence ratio is the entire story, and it is deliberate. Milestones exist to move risk back onto a seller when a buyer is unsure, and argenx declined them on a ten-patient placebo arm. That only makes sense if the purchase is the mechanism rather than the vitiligo readout. Blocking CD122 while sparing CD25 gives you suppression of pathogenic T cells and NK cells without switching off regulatory T cells, which is a cleaner proposition than broad cytokine blockade and is the argument for paying once rather than in instalments. The vitiligo data is the permission slip, not the asset.
• Competitive frame: argenx signed on 26 July, three days before the European Commission approved AbbVie’s RINVOQ in both non-segmental vitiligo and severe alopecia areata, which are two of FB102’s three named indications. That timing is not misfortune, it is the reason the mechanism matters. A JAK inhibitor now holds the first systemic label in Europe, and the class safety conversation around JAKs in adolescents with non-life-threatening disease is precisely where a Treg-sparing antibody makes its case. Celiac is the uncontested ground: 2.5 million US patients, a quarter unresponsive to gluten-free diet, and no approved drug therapy at all.
• What to watch: the offer expires 26 August and, under Section 251(h) with a recommending board, there is no vote to lose, so the closing risk is thin. The real date is Phase 2 vitiligo in the second half of this year, which lands after argenx already owns the asset and with a properly sized control arm. If that readout holds the Week 24 separation, the absence of milestones will look like conviction. If it does not, argenx will have paid $2.2 billion in full for a signal generated in ten placebo patients, and every board negotiating a no-milestone structure next year will be shown this deal.